key: cord-318519-8sny5uq1
authors: Hagan, Katherine B.; Raju, Gottumukkala; Carlson, Richard; Gottumukkala, Vijaya
title: To the Editor
date: 2020-05-12
journal: Anesth Analg
DOI: 10.1213/ane.0000000000004962
sha: 
doc_id: 318519
cord_uid: 8sny5uq1

nan

To the Editor W e thank Drs Rah and Platovsky 1 for bringing attention to special considerations for gastrointestinal (GI) endoscopic procedures in an ambulatory care setting during the coronavirus disease of 2019 (COVID-19) pandemic. As institutions endeavor to ensure safe endoscopic practices for emergent, urgent, and elective cases, distribution of personal protective equipment (PPE) and access to reliable SARS-CoV-2 (COVID-19) testing remain key issues.

We would join Drs Rah and Platovsky 1 in arguing that endoscopy is especially high risk for several reasons: (1) upper and lower endoscopies are aerosolgenerating procedures (AGPs) 2 ; (2) these procedures involve bodily fluids that are known to carry the virus 3,4 ; (3) the procedure requires the gastroenterologist, technologist, and, at times, anesthesia provider to stand in close proximity to the site of aerosolization, 5 and, in the case of upper endoscopy, this places all 3 providers well within the 2-m zone for aerosolization; (4) many therapeutic procedures last ≥2 hours, with COVID-19 well-documented in upper airway secretions and feces 3, 4 ; and (5) increased infectious risk to faculty and staff in the GI suite due to the higher case volumes and prolonged AGPs in these areas. Endoscopy procedures with anesthesia pose additional risk for transmission of COVID-19 infection to providers in the room due to intubation and extubation, which are aerosolizing procedures. Even moderate sedation with total intravenous anesthesia (TIVA) has added risks as patients without a secured airway tend to cough, aerosolize secretions, and/or require manual airway support (including intubation) in the midst of the procedure. Therefore, we strongly recommend PPE use per Center for Disease Control (CDC) guidelines for AGPs 6 and for all procedures in the GI endoscopy suite during the COVID-19 pandemic. It is prudent that, at a minimum, all patients with risk factors (travel within 14 days, exposure to a positive patient, fever with or without respiratory symptoms) be tested the day before their procedure. Furthermore, as highly sensitive diagnostic tests (RT-PCR) for COVID-19 become widely available for routine use, we urge institutions to be cognizant of the risks associated with GI procedures and endeavor to institute testing of asymptomatic patients in these areas. We must remember that procedural areas such as endoscopy are not only associated with high patient volumes areas but also associated with prolonged AGP interventions.

Determining urgent/emergent status of gastrointestinal (GI) endoscopic procedures in an ambulatory care setting during the coronavirus disease of 2019 (COVID-19) pandemic: additional Factors that need to be considered

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Staffing at ambulatory endoscopy centers in the United States: practice, trends, and rationale


